1. Home
  2. Knowledge Base
  3. References
  4. Disrupted serotonergic system in patients with pulmonary hypertension may serve as novel biomarkers new therapeutic targets and to assess severity, progression and response to treatment.

Disrupted serotonergic system in patients with pulmonary hypertension may serve as novel biomarkers new therapeutic targets and to assess severity, progression and response to treatment.

Kirillova V, Prosviryakov E (2012) Disrupted serotonergic system in patients with pulmonary hypertension may serve as novel biomarkers new therapeutic targets and to assess severity, progression and response to treatment. Cardiovasc Res 93 Suppl 1:P209. European Society of Cardiology, Munich Germany. PMID: 909090

Summary: At the Frontiers in Cardiovascular Biology meeting in London the authors presented work examining the role serotonin and serotonin transporters play in pulmonary hypertension. Anti-SERT (Cat. #AB-N09, 1:500) was used in immunohistochemistry to detect the serotonin transporter in the myocardium.  The data demonstrate that serotonin levels in the blood and serotonin transporter levels in the myocardium are both increased in patients with pulmonary hypertension.

Related Products: Antibody to Serotonin Transporter (SERT, Cat. #AB-N09)

Shopping Cart
Scroll to Top